BBI and Lateral Dx Partnership
By combining Lateral Dx’s advanced assay development capabilities with BBI Solutions’ ISO 13485-certified, scalable manufacturing infrastructure, the partnership enables customers to move from concept to commercial-scale production with reduced development timelines and enhanced product performance.
Under the agreement:
Lateral Dx will lead the design and optimisation of high-performance lateral flow assays, leveraging advanced antibody screening services, reader technologies, novel materials, quantitative development capabilities, and user-centric design principles.
BBI Solutions will provide end-to-end manufacturing, quality assurance, and regulatory support from its state-of-the-art facilities in Crumlin, ensuring consistent quality and scalability.
“The lateral flow diagnostics market continues to expand beyond traditional applications, and customers need partners who can deliver both innovation and manufacturing excellence,” said Mat Hobbs, Chief Commercial Officer at BBI Solutions. “Lateral Dx brings proven expertise in pushing the boundaries of sensitivity and specificity, which complements our track record of producing over 25 million diagnostic components annually. This partnership creates a genuinely streamlined pathway from initial design to commercial launch.”
“This partnership marks a significant milestone for Lateral Dx and addresses a critical need in the diagnostics industry,” added Richard Campbell, Managing Director at Lateral Dx. “By integrating our agile development approach with BBI’s proven manufacturing infrastructure, we’re creating a truly turnkey solution that dramatically reduces time-to-market and technical risk for our customers.”
The collaboration is already underway with several development projects, and a major commercial program is planned for 2026. This initiative will progress through full development to scaled production, showcasing the partnership’s ability to deliver end-to-end solutions that meet real-world diagnostic needs.
Both companies are committed to advancing global health through accessible, reliable diagnostics and will continue integrating emerging technologies—from enhanced signal amplification to next-generation materials and device formats—to maintain their competitive edge in the rapidly evolving lateral flow market.
About BBI Solutions
BBI Solutions is a trusted global provider of high-quality reagents and IVD manufacturing services. With decades of experience supporting diagnostic developers and manufacturers, BBI’s facilities are ISO 13485-certified and designed to deliver scale, consistency, and technical excellence throughout product lifecycles.
About Lateral Dx
Lateral Dx specialises in lateral flow assay development, transforming complex diagnostic challenges into practical, market-ready solutions. Based in Alloa, Scotland, the company’s expertise spans advanced conjugate chemistry, novel detection methods, and user-centric design, serving clients across human health, veterinary, food safety, and environmental sectors.
Media Contacts:
BBI Solutions Pamela Pirrit, Marketing Director, pamelapirrit@bbisolutions.com +44(0)7946 105594
Lateral Dx Richard Campbell Managing Director technical@lateraldx.com +44(0)1259 793041